Recently, we confirmed that a single dose of trastuzumab-derived HER2-specific CAR T cells, as actively moving living drugs, could penetrate and eradicate established trastuzumab-resistant MDA-HER2 and JIMT-1 tumor xenografts while saturating doses of soluble trastuzumab co-administered with multiple doses of CD16.176V.NK-92 effector cells only transiently retarded tumor growth (9). This evidence concerns the gene ERBB2 and neoplasm.